A disintegrin and metalloprotease 12 (ADAM12) is a prognostic factor in resected pathological stage I lung adenocarcinoma

✍ Scribed by Nobuya Mino; Ryo Miyahara; Ei Nakayama; Tsuyoshi Takahashi; Ayuko Takahashi; Shotaro Iwakiri; Makoto Sonobe; Kenichi Okubo; Toshiki Hirata; Atsuko Sehara; Hiroshi Date

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 133 KB
• Volume: 100
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.21313

✦ Synopsis

Abstract

Background and Objectives

A disintegrin and metalloprotease 12 (ADAM12) has multiple domains and functions, and it plays important roles in the development of cancer. We conducted a retrospective study to determine whether the expression of the membrane type of ADAM12 (ADAM12‐L) could be a prognostic factor in resected pathological (p‐) stage I lung adenocarcinoma.

Methods

ADAM12‐L mRNA expression was quantified by a reverse‐transcription polymerase chain reaction in tissue samples from 84 completely resected p‐stage I lung adenocarcinoma patients. The patients were divided into ADAM12‐L‐Low and ADAM12‐L‐High groups, and correlations with clinicopathologic features were obtained.

Results

Five‐year survival rates of the ADAM12‐L‐Low and ADAM12‐L‐High groups were 95.1% and 71.9%, respectively. The postoperative prognosis for the ADAM12‐L‐High group was significantly poorer than for the ADAM12‐L‐Low group (P = 0.006). Multivariate analysis confirmed that high expression of ADAM12‐L was an independent factor for poor prognosis (P = 0.007, hazard ratio 8.288). The ADAM12‐L‐High group was less differentiated and had a significantly higher rate of cancer recurrence.

Conclusions

ADAM12‐L mRNA expression is an independent prognostic factor in resected p‐stage I lung adenocarcinoma, and is significantly correlated with tumor differentiation stage and postoperative cancer recurrence. J. Surg. Oncol. 2009;100:267–272. © 2009 Wiley‐Liss, Inc.